Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.

PURPOSE In children with intermediate risk of relapse of acute lymphoblastic leukemia (ALL), it is essential to identify patients in need of treatment intensification. We hypothesized that the prognosis of patients with unsatisfactory reduction of minimal residual disease (MRD) can be improved by allogeneic hematopoietic stem-cell transplantation (HSCT). PATIENTS AND METHODS In the Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group (ALL-REZ BFM) 2002, patients with an MRD level of ≥ 10(-3) (n = 99) at the end of induction therapy were allocated to HSCT, whereas those with an MRD level less than 10(-3) (n = 109) continued to receive chemotherapy. MRD was quantified by real-time polymerase chain reaction for clone-specific T-cell receptor/immunoglobulin gene rearrangements. RESULTS The probability of event-free survival for patients with MRD ≥ 10(-3) was 64% ± 5% in ALL-REZ BFM 2002 compared with 18% ± 7% in the predecessor study ALL-REZ BFM P95/96 (P < .001). This was mainly achieved by reducing the cumulative incidence of subsequent relapse (CIR) at 8 years from 59% ± 9% to 27% ± 5% (P < .001). The favorable prognosis of patients with MRD less than 10(-3) could be confirmed in those with a late combined or isolated bone marrow B-cell precursor (BCP) -ALL relapse (CIR, 20% ± 5%), whereas patients with an early combined BCP-ALL relapse had an unfavorable outcome (CIR, 63% ± 13%; P < .001). CONCLUSION Allogeneic HSCT markedly improved the prognosis of patients with intermediate risk of relapse of ALL and unsatisfactory MRD response. As a result, outcomes in this group approximated those of patients with favorable MRD response. Patients with early combined relapse require treatment intensification even in case of favorable MRD response, demonstrating the prognostic impact of time to relapse.

[1]  S. Hunger,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.

[2]  Douglas G Altman,et al.  Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.

[3]  J. V. van Dongen,et al.  Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. , 2004, Blood.

[4]  J. V. van Dongen,et al.  Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. , 1999, Blood.

[5]  T. Szczepański,et al.  Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations , 1997, Leukemia.

[6]  A. Órfão,et al.  The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). , 1998, Blood.

[7]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[8]  F. Aversa,et al.  Competing risk analysis using R: an easy guide for clinicians , 2007, Bone Marrow Transplantation.

[9]  Dario Campana,et al.  Minimal residual disease monitoring in childhood acute lymphoblastic leukemia , 2012, Current opinion in hematology.

[10]  D. Campana,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse , 2004, Leukemia.

[11]  G. Henze,et al.  Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. , 1993, Medical and pediatric oncology.

[12]  A. Borkhardt,et al.  Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. , 2013, European journal of cancer.

[13]  J. V. van Dongen,et al.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.

[14]  A. Porwit,et al.  Acute leukemias of ambiguous lineage. , 2012, Seminars in diagnostic pathology.

[15]  D. Campana.  Progress of Minimal Residual Disease Studies in Childhood Acute Leukemia , 2010, Current hematologic malignancy reports.

[16]  M. Borowitz,et al.  Acute leukaemias of ambiguous lineage. . , 2001 .

[17]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[18]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[19]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[20]  J. Cayuela,et al.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.

[21]  P. Gaynon.  Childhood acute lymphoblastic leukaemia and relapse , 2005, British journal of haematology.

[22]  C. Eckert,et al.  Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia , 2001, The Lancet.

[23]  C. Eckert,et al.  Real-time PCR to detect minimal residual disease in childhood ALL. , 2004, Methods in molecular medicine.

[24]  C. Eckert,et al.  Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes , 2003, Leukemia.

[25]  M. Valsecchi,et al.  Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia , 2011, British journal of haematology.

[26]  D. Campana.  Molecular determinants of treatment response in acute lymphoblastic leukemia. , 2008, Hematology. American Society of Hematology. Education Program.

[27]  Great,et al.  Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial , 2010, The Lancet.

[28]  Dario Campana,et al.  Minimal residual disease in acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.

[29]  M. Schrappe,et al.  Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials , 2008, Bone Marrow Transplantation.

[30]  G. Henze,et al.  Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. , 2003, Blood.

[31]  Treatment of Relapsed Acute Lymphoblastic Leukemia , 2003 .

[32]  M. Schrappe,et al.  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Hunger,et al.  Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.